证券代码：688193 证券简称：仁度生物 公告编号：2023-031 重要内容提示： 上海仁度生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 1 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司经营 成果、财务状况，公司计划于 2023 年 9 月 5 日（星期二）下午 13:00-15:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 9 月 5 日（星期二）下午 13:00-15:00 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 上海仁度生物科技股份有限公司 关于参加 2023 半年度医疗器械及医疗设备行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公 ...

根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上 市公司信息披露管理办法》及其他公司内部制度的有关规定，公司对 2023 年限 制性股票激励计划（以下简称"本激励计划"）采取了充分必要的保密措施，对 本激励计划的内幕信息知情人进行了登记。根据《管理办法》《上海证券交易所 科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激励信息 披露》等法律、法规和规范性文件的相关规定，公司通过中国证券登记结算有限 责任公司上海分公司对本激励计划的内幕信息知情人在本激励计划草案公开披 露前 6 个月内（即 2023 年 2 月 1 日至 2023 年 7 月 31 日，以下简称"自查期 间"）买卖公司股票的情况进行自查，具体情况如下： 一、核查的范围与程序 1、核查对象为本激励计划的内幕信息知情人（以下简称"核查对象"）。 2、本激励计划的内幕信息知情人均填报了《内幕信息知情人登记表》。 3、公司向中国证券登记结算有限公司上海分公司就核查对象在自查期间买 卖公司股票情况进行了查询，并由中国证券登记结算有限公司上海分公司出具了 证券代码：688193 证券简称：仁度生物 公告编号：2023-0 ...

证券代码：688193 证券简称：仁度生物 公告编号：2023-029 上海仁度生物科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1、 公司在任董事 7 人，出席 7 人； 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 18 | | --- | --- | | 普通股股东人数 | 18 | | 2、出席会议的股东所持有的表决权数量 | 25,337,743 | | 普通股股东所持有表决权数量 | 25,337,743 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 63.3444 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 63.3444 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由董事会召集，董 ...

北京市嘉源律师事务所 关于上海仁度生物科技股份有限公司 2023 年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 童师事务所 A YUAN LAW OFFICES 法律意见书 嘉源(2023)-04-627 北京市嘉源律师事务所(以下简称"本所")接受上海仁度生物科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东大会规则》(以下简称"《股东大会规则》")等现 行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以 及《上海仁度生物科技股份有限公司章程》(以下简称"《公司章程》")的有关规 定,指派本所律师对公司 2023年第一次临时股东大会(以下简称"本次股东大 会")进行见证,并依法出具本法律意见书。 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海仁度生物科技股份有限公司 北京市嘉源律师事务所 关于上海仁度生物科技股份有限公司 2023 年第一次临时股东大会 ...

1 中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 2023 年半年度持续督导跟踪报告 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁度 生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在科创 板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等相关规定，负责仁度生物上市后的持续督导工作，并出具本持续督导半年度跟踪报 告，具体情况如下： 一、持续督导工作情况 | 序号 | 工作名称 | 实施情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针 | 保荐机构已建立健全并有效执行了持 | | | 对具体的持续督导工作制定相应的工作计划。 | 续督导制度，并制定了相应的工作计 | | | | 划。 | | | 根据中国证券监督管理委员会（以下简称"中 | 保荐机构已与仁度生物签订保荐协 | | | 国证监会"）相关规定，在持续督导工作开始 | | | 2 | 前，与上市公司签署持续督导协议，明确双 ...

证券代码：688193 证券简称：仁度生物 公告编号：2023-028 上海仁度生物科技股份有限公司监事会 关于公司 2023 年限制性股票激励计划 激励对象名单的审核意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）于 2023 年 7 月 31 日 召开的第一届董事会第十六次会议、第一届监事会第十三次会议审议通过了《关 于<上海仁度生物科技股份有限公司 2023 年限制性股票激励计划（草案）>及其 摘要的议案》等议案。根据《上市公司股权激励管理办法》（以下简称"《管理 办法》"）的相关规定，公司对《上海仁度生物科技股份有限公司 2023 年限制 性股票激励计划（草案）》（以下简称"本激励计划"）中确定的激励对象名单 在公司内部进行了公示。公司监事会根据《管理办法》相关规定，在征询公示意 见后对拟激励对象名单进行核查，相关公示情况及核查结果如下： 一、公示情况及核查方式 公司于 2023 年 8 月 1 日、2023 年 8 月 8 日在上海证券交易所网站 ...

上海仁度生物科技股份有限公司 2023 年第一次临时股东大会会议资料 证券代码：688193 证券简称：仁度生物 上海仁度生物科技股份有限公司 2023 年第一次临时股东大会会议资料 2023 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"证券法"）《上市公司股东大会规则》以及《上 海仁度生物科技股份有限公司章程》（以下简称"《公司章程》"）《上海仁度生物 科技股份有限公司股东大会议事规则》等相关规定，上海仁度生物科技股份有限 公司（以下简称"公司"）特制定 2023 年第一次临时股东大会会议须知： 一、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，出席 会议的股东及股东代理人须在会议召开前 15 分钟到会议现场办理签到手续，并 请按规定出示证券账户卡、身份证明文件或企业营业执照/注册证书复印件（加 盖公章）、授权委托书等，经验证后领取会议资料，方可出席会议。会议开始后， 会议登记应当终止，由会议主持人宣布现场出席会议的股东和代理人人数及所 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2023, representing a 20% increase compared to the same period last year [1]. - The company's operating revenue for the first half of 2023 was ¥80,029,969.73, a decrease of 52.83% compared to ¥169,661,995.80 in the same period last year [21]. - The net profit attributable to shareholders for the first half of 2023 was -¥10,192,633.27, representing a decline of 146.50% from ¥21,921,636.24 in the previous year [21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,555,699.40, a decrease of 185.06% compared to ¥17,112,955.88 in the same period last year [21]. - The net cash flow from operating activities was -¥13,947,402.37, worsening from -¥5,296,678.95 in the previous year [21]. - The basic earnings per share for the first half of 2023 were -¥0.25, a decline of 139.68% from ¥0.63 in the same period last year [22]. - The diluted earnings per share for the first half of 2023 were -¥0.25, a decrease of 140.32% compared to ¥0.62 in the previous year [22]. - The company's total comprehensive income for the first half of 2023 was a loss of CNY 8,677,861.92, compared to a profit of CNY 22,320,634.80 in the same period of 2022 [196]. Research and Development - Research and development expenses increased by 30% to 150 million RMB, focusing on enhancing the SAT technology platform [1]. - Research and development investment increased by 26.76% year-on-year, accounting for 23.24% of operating revenue [24]. - The company reported a total R&D expenditure of ¥18,600,816.46 for the current period, representing a 26.76% increase compared to ¥14,674,416.73 in the same period last year [48]. - The company has developed core technologies in molecular diagnostics, including RNA real-time fluorescence isothermal amplification technology and multiple RNA amplification detection technology, all sourced from independent research and development [42]. - The company has seen a significant increase in R&D personnel and compensation, contributing to the rise in R&D expenditures [49]. Market Expansion and Product Development - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024 [1]. - New product launches include a novel RNA detection kit, expected to contribute an additional 100 million RMB in revenue by Q4 2023 [1]. - The company has developed a complete molecular diagnostic industry chain, including core raw materials, reagents, instruments, and third-party testing services [28]. - The company aims to expand its market presence by providing systematic solutions to medical institutions and independent laboratories [32]. - The company has launched innovative diagnostic products, including the world's first HBV RNA detection kit, which offers significant advantages over traditional HBV DNA testing [62]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance [1]. - The company faces risks related to the loss of core technical personnel, which could adversely affect ongoing and future projects [72]. - There is a risk of intensified market competition, particularly in the RNA detection market, as many new entrants are emerging [74]. - The company is exposed to potential changes in tax incentives and government subsidies, which could negatively impact its financial performance [77]. - The global macroeconomic environment may affect healthcare spending, potentially slowing demand for in vitro diagnostic products [79]. Shareholder and Governance Commitments - The controlling shareholder commits not to engage in any competing business during their control period, ensuring no direct or indirect competition with the company [107]. - The company commits to a profit distribution policy prioritizing cash dividends, with a minimum cash dividend ratio of 80% during mature stages without major capital expenditures [126]. - The company will ensure that any share reduction does not violate commitments made during the IPO process [113]. - The company has committed to ensuring the authenticity, accuracy, and completeness of its IPO prospectus and related documents, taking legal responsibility for any false statements or omissions that may cause investor losses [131]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders if necessary [130]. Environmental and Social Responsibility - The company invested 4.10 million yuan in environmental protection during the reporting period [99]. - The company has established a wastewater treatment system that complies with Shanghai's local standards for wastewater discharge [100]. - Solid waste is managed by a qualified third-party hazardous waste disposal company, ensuring proper handling of waste materials [101]. - The company has implemented noise reduction measures to meet the industrial noise emission standards [101]. - The company has integrated energy-saving and emission reduction concepts into its daily operations [103].

Financial Performance - The net profit attributable to shareholders for 2022 was RMB 23,331,394.53, representing a profit margin of approximately 21.43% of the total profit distributed to shareholders[6]. - The company plans to distribute a cash dividend of RMB 1.25 per 10 shares, totaling RMB 5,000,000.00, based on a total share capital of 40 million shares as of December 31, 2022[6]. - As of December 31, 2022, the company's distributable profits amounted to RMB 100,659,989.86[6]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2022 was approximately ¥303.85 million, representing a year-over-year increase of 3.95% compared to ¥292.31 million in 2021[23]. - Net profit attributable to shareholders decreased by 63.89% to approximately ¥23.33 million from ¥64.62 million in 2021[23]. - The basic earnings per share fell by 71.16% to ¥0.62, while diluted earnings per share decreased by 71.36% to ¥0.61[24]. - The net cash flow from operating activities dropped by 107.51%, resulting in a negative cash flow of approximately ¥4.09 million[25]. - The company's total assets increased by 187.56% to approximately ¥1.09 billion, up from ¥378.61 million in 2021[23]. - The company reported a total revenue of 13,000.00 million RMB, with a net profit of 3,155.65 million RMB, reflecting a significant increase in performance compared to the previous year[81]. Research and Development - Research and development expenses grew by 29.91%, accounting for 11.25% of operating revenue, up from 9% in the previous year[24]. - The company applied for 50 patents, including 28 invention patents and 22 utility model patents, enhancing its competitive barrier[36]. - The company has developed a fully automated nucleic acid detection system that can process samples without manual intervention, achieving a "sample in, result out" workflow, significantly improving efficiency[45]. - The company has established a comprehensive core technology system for molecular diagnostic reagents, enhancing its competitive edge in the market[73]. - The total R&D investment for the year was approximately ¥34.19 million, representing a 29.91% increase from the previous year, with R&D expenses accounting for 11.25% of total revenue[78]. Market and Product Development - The company is actively involved in the development of new diagnostic technologies and products, aiming to expand its market presence[12]. - The company’s strategic focus includes enhancing its product offerings and exploring potential mergers and acquisitions to drive growth[12]. - The company has developed a range of molecular diagnostic reagent products, including the first SAT-based nucleic acid test kits for Chlamydia trachomatis and Neisseria gonorrhoeae in China, addressing unmet clinical needs[41]. - The company launched the world's first HBV RNA detection product for hepatitis B, which is now used in several provinces including Shandong and Fujian[64]. - The company aims to become a leading developer and supplier of molecular diagnostic products, focusing on unmet clinical needs in the RNA diagnostics field[138]. Corporate Governance - The company has not yet achieved profitability since its listing[4]. - The company does not have any special arrangements for corporate governance[8]. - The company has established a governance framework that includes a board of directors, supervisory board, and various specialized committees to ensure effective oversight and decision-making[142]. - There were no significant differences between the company's governance practices and the regulations set forth by the China Securities Regulatory Commission[142]. - The company has maintained a presence in academic institutions, with board members holding positions at universities, which may facilitate research collaborations and innovation[155]. Operational Risks and Challenges - The company faces challenges due to a shift in revenue structure, leading to a decrease in gross profit contribution[26]. - The company is exposed to competition from both domestic and international players, which may impact its market position if it cannot maintain technological leadership[96]. - The company must navigate regulatory challenges, as new products require extensive approval processes that can take 3-5 years[94]. - The company is at risk of new product development failures due to high costs, long cycles, and potential misalignment with market needs[93]. - The company faces risks related to significant revenue declines if conventional business growth cannot offset declines in pandemic-related business[92]. Environmental and Social Responsibility - The company invested 4.8 million yuan in environmental protection during the reporting period[191]. - The company is not listed as a key pollutant discharge unit and has no instances of exceeding emission standards[192]. - The company has established an environmental protection management system and has clear responsibilities for waste disposal and emissions[195]. - The company donated 81.23 million yuan to local Red Cross societies to support pandemic prevention efforts[197]. Future Outlook - The company anticipates continued growth in the in vitro diagnostic market, driven by an aging population and rising healthcare demands[134]. - The molecular diagnostics market is expected to lead the in vitro diagnostics industry, with applications in various medical fields[134]. - The molecular diagnostics market in China is expected to grow rapidly, driven by increasing clinical demand and technological advancements, with a focus on RNA diagnostics[135]. - The Chinese government is promoting a health-centered approach, emphasizing early screening and prevention in infectious disease management, which will benefit RNA diagnostics[137].

Financial Performance - The company's operating revenue for Q1 2023 was ¥38,766,500.34, representing a decrease of 58.44% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥6,392,335.66, reflecting a decline of 138.03% year-over-year[5]. - Basic and diluted earnings per share were both -¥0.16, down 128.57% from the same period last year[6]. - Total operating revenue for Q1 2023 was ¥38,766,500.34, a decrease of 58.5% compared to ¥93,280,166.18 in Q1 2022[20]. - Net profit for Q1 2023 was a loss of ¥6,392,335.66, compared to a profit of ¥16,806,634.77 in Q1 2022, representing a significant decline[20]. - The company experienced a comprehensive loss of ¥6,909,010.22 in Q1 2023, compared to a comprehensive income of ¥16,784,019.05 in Q1 2022[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥6,213,384.20, a decrease of 204.23% compared to the previous year[6]. - In Q1 2023, the net cash flow from operating activities was -$6,213,384.20, a significant decline from $5,961,279.66 in Q1 2022[24]. - Total cash inflow from operating activities was $67,228,828.74, down from $74,655,779.92 in the same quarter last year, representing a decrease of approximately 10.5%[24]. - Cash outflow from operating activities increased to $73,442,212.94 from $68,694,500.26, marking an increase of about 6.5% year-over-year[24]. - The total cash and cash equivalents at the end of Q1 2023 were $273,236,061.29, down from $875,430,465.48 at the end of Q1 2022, reflecting a decrease of approximately 68.9%[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,066,374,019.29, a decrease of 2.05% from the end of the previous year[6]. - Total liabilities decreased to ¥110,652,691.07 in Q1 2023 from ¥127,337,004.79 in Q1 2022, indicating a reduction of 13.1%[17]. - The company's total assets as of Q1 2023 were ¥1,066,374,019.29, a decrease from ¥1,088,721,710.38 in the previous year[17]. Research and Development - Research and development expenses totaled ¥8,518,167.13, an increase of 17.21% year-over-year, accounting for 21.97% of operating revenue, up 12.35 percentage points[6]. - Research and development expenses increased to ¥8,518,167.13 in Q1 2023, up from ¥7,267,729.68 in Q1 2022, reflecting a focus on innovation[20]. - The company is accelerating multiple ongoing projects to enhance future growth potential, which contributed to the increase in R&D expenses[9]. Shareholder Information - The top shareholder,居金良, holds 19.65% of the shares with a total of 7,858,357 shares[12]. - MING LI INVESTMENTS LIMITED is the second-largest shareholder with 15.44%, holding 6,176,624 shares[12]. - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[13]. Operational Insights - The decline in revenue was attributed to a significant drop in pandemic-related testing products, despite a recovery in routine testing reagent business[9]. - The report indicates no significant changes in the company's operational strategies or new product developments during the quarter[14]. - The company has not provided specific guidance for future performance or market expansion plans in this report[14].